Several clinical trials investigating the efficacy of checkpoint inhibitors have already been initiated in HER2-positive breast cancer (NCT02734004, NCT02605915, NCT02318901, NCT02403271) and HER2-positive gastric cancer (NCT02689284). The gene discussed is ERBB2; the disease is breast cancer.